UNICA IRIS Institutional Research Information System

DE LOGU, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 174.195
NA - Nord America 12.191
AS - Asia 4.783
SA - Sud America 748
Continente sconosciuto - Info sul continente non disponibili 258
AF - Africa 115
OC - Oceania 3
Totale 192.293
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 170.507
US - Stati Uniti d'America 11.926
SG - Singapore 1.885
CN - Cina 1.804
UA - Ucraina 1.051
DE - Germania 615
SE - Svezia 615
FI - Finlandia 560
BR - Brasile 553
VN - Vietnam 351
GB - Regno Unito 311
FR - Francia 279
HK - Hong Kong 141
CA - Canada 130
IN - India 121
BD - Bangladesh 120
KR - Corea 113
MX - Messico 72
AR - Argentina 52
RU - Federazione Russa 48
MA - Marocco 47
EC - Ecuador 44
NL - Olanda 43
IQ - Iraq 38
CO - Colombia 29
JP - Giappone 27
TR - Turchia 25
BE - Belgio 22
ES - Italia 22
ID - Indonesia 22
PL - Polonia 22
ZA - Sudafrica 20
PE - Perù 19
IL - Israele 18
PK - Pakistan 18
VE - Venezuela 15
CR - Costa Rica 14
UZ - Uzbekistan 12
CH - Svizzera 11
CL - Cile 11
IE - Irlanda 11
MD - Moldavia 11
PH - Filippine 11
PY - Paraguay 11
SA - Arabia Saudita 11
AT - Austria 10
EG - Egitto 9
JM - Giamaica 9
KE - Kenya 8
PR - Porto Rico 8
UY - Uruguay 8
AE - Emirati Arabi Uniti 7
SV - El Salvador 7
TN - Tunisia 7
TT - Trinidad e Tobago 7
AL - Albania 6
AZ - Azerbaigian 6
BO - Bolivia 6
EU - Europa 6
HN - Honduras 6
JO - Giordania 6
DZ - Algeria 5
IR - Iran 5
MY - Malesia 5
RO - Romania 5
BY - Bielorussia 4
DK - Danimarca 4
HU - Ungheria 4
KZ - Kazakistan 4
PT - Portogallo 4
SC - Seychelles 4
SM - San Marino 4
TW - Taiwan 4
AU - Australia 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
EE - Estonia 3
GE - Georgia 3
KG - Kirghizistan 3
LT - Lituania 3
MU - Mauritius 3
OM - Oman 3
SI - Slovenia 3
SN - Senegal 3
TH - Thailandia 3
BG - Bulgaria 2
BN - Brunei Darussalam 2
CG - Congo 2
CU - Cuba 2
CW - ???statistics.table.value.countryCode.CW??? 2
GR - Grecia 2
GT - Guatemala 2
HR - Croazia 2
LB - Libano 2
LK - Sri Lanka 2
LV - Lettonia 2
NG - Nigeria 2
NP - Nepal 2
PS - Palestinian Territory 2
QA - Qatar 2
Totale 192.022
Salva come PNG Salva come JPEG
Città #
Cagliari 165.839
Uta 3.055
Ashburn 1.672
San Jose 871
Singapore 866
Chandler 764
Woodbridge 635
Fairfield 625
Jacksonville 600
Boardman 590
Ann Arbor 491
Dallas 469
Houston 410
Nyköping 406
Helsinki 403
Wilmington 330
Beijing 269
New York 268
Seattle 261
Munich 257
Los Angeles 236
Cambridge 214
Hefei 209
Council Bluffs 187
Boston 181
Santa Clara 163
Nanjing 162
Lauterbourg 139
Hong Kong 128
Dearborn 125
Ho Chi Minh City 117
Milan 117
Seoul 112
Rome 97
Buffalo 93
São Paulo 87
The Dalles 87
Shanghai 85
Chicago 82
Hanoi 80
Toronto 71
Redwood City 68
Shenyang 61
Nanchang 59
Tianjin 57
Verona 52
Hebei 49
Changsha 45
Princeton 43
Atlanta 42
Guangzhou 36
San Diego 35
Jiaxing 33
Casablanca 31
Orange 30
London 29
Washington 29
Brooklyn 28
Chennai 28
Columbus 28
Zhengzhou 28
Jinan 26
Orem 25
Phoenix 24
Norwalk 23
Florence 22
Bologna 21
Ningbo 21
Redondo Beach 19
Tokyo 19
Brussels 18
Naples 17
Nuremberg 17
San Francisco 17
Elk Grove Village 16
Frankfurt am Main 16
Quito 16
Rio de Janeiro 16
Hangzhou 15
Sassari 15
Warsaw 15
Auburn Hills 14
Dhaka 14
Genoa 14
Johannesburg 14
Haiphong 13
Mountain View 13
Salt Lake City 13
Catania 12
Denver 12
Palermo 12
Pune 12
Saint Petersburg 12
Turin 12
Baghdad 11
Bari 11
Caserta 11
Curitiba 11
Da Nang 11
Jyväskylä 11
Totale 183.275
Salva come PNG Salva come JPEG
Nome #
Exploring the thiazole scaffold for the identification of new agents for the treatment of fluconazole resistant Candida 5.082
Attività antimicobatterica di nuovi S-alchilisotiosemicarbazoni e potenziamento dell'attività di rifabutina, rifampicina e amikacina nei confronti di Mycobacterium avium 4.619
Limonoids from Melia azedarach fruits as inhibitors of flaviviruses and mycobacterium tubercolosis 4.518
2-(2-cycloalkylidene hydrazin-1-yl)-4-aryl-1,3-thiazoles: a promising class of antifungal agents 4.444
Ungeremine effectively targets mammalian as well as bacterial type I and type II topoisomerases 3.517
Antiherpevirus activity of Artemisia arborescens essential oil and inhibition of lateral diffusion in Vero cells 3.089
MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212 2.783
Discovery of in vitro antitubercular agents through in silico ligand-based approaches 2.391
Design, synthesis, SAR and biological investigation of 3-(carboxymethyl)rhodanine and aminothiazole inhibitors of Mycobacterium tuberculosis Zmp1 2.357
Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B 2.308
New pyrrole derivatives of BM 212: a new class of antimycobacterial agents. Design, synthesis, biological evaluation and study of their mode of action. 2.270
Terapia delle infezioni sostenute da Candida spp.: nuovi approcci mediante derivati isotiosemicarbazonici. 2.241
Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection 2.230
Developing pyrrole-derived antimycobacterial agents: a rational lead optimization approach 2.218
HPLC-DAD-MS analysis and antiviral activity of different extracts and isolated costituents from Bituminaria bituminosa 2.189
Synthesis, biological evaluation and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis 2.131
Imidazole and 1,2,4-triazole-based derivatives gifted with antitubercular activity: Cytotoxicity and computational assessment 2.130
In vitro activity of 2-cyclohexylidenhydrazo-4-phenil-thiazole compared with those of amphotericin b and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans 2.127
Improving the physical chemical properties of a very promising class of pyrrole antimycobacterial agents 2.077
Antimycobacterial activity of new N1-[1-[1-aryl-3-[4-(1H-imidazol-1-yl)phenyl]-3-oxo]propyl]-pyridine-2-carboxamidrazone derivatives 2.038
2-Acylhydrazino-5-arylpyrrole derivatives: Synthesis and antifungal activity evaluation 2.024
In vivo potent BM635 analogue with improved drug-like properties 2.013
Rifampicin-loaded liposomes for the passive targeting to alveolar macrophages: in vitro and in vivo evaluation 1.996
1,5-Diaryl-2-ethyl pyrrole derivatives as antimycobacterial agents: design, synthesis and microbiological evaluation 1.987
The MmpL3 protein is responsible for resistance to BM212, a lead antitubercular drug 1.968
Synthesis, biological evaluation, and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis: part 2. Synthesis of rigid pyrazolones 1.959
Synthesis and anti-microbial activity evaluation of some new 1-benzoyl-isothiosemicarbazides. 1.954
null 1.953
null 1.949
1,5-Diphenylpyrrole derivatives as antimycobacterial agents. Probing the influence on antimycobacterial activity of lipophilic substituents at the phenyl rings 1.834
null 1.829
Design, synthesis and antimycobacterial activity of benzoxazinone derivatives and open-ring analogues: Preliminary data and computational analysis 1.818
Nuove strategie per lo sviluppo di farmaci antitubercolari: caratterizzazione di target alternativi e di fattori di virulenza in Mycobacterium tuberculosis 1.817
Sherris. Microbiologia medica 1.794
null 1.749
Individuazione di nuovi target in MDR e XDR Mycobacterium tuberculosis mediante 1,5-difenil- e 1,5-diaril-2-etil-pirroli per lo sviluppo di nuovi agenti antitubercolari 1.721
Synthesis and anti-microbial activity of isothiosemicarbazones and cyclic analogues 1.684
Synthesis and antimicrobial activity of novel arylidenisothiosemicarbazones 1.684
Attività fungicida di analoghi ciclici isotiosemicarbazonici nei confronti di isolati clinici di Candida spp. 1.660
Synthesis and biological evaluation of new enantiomerically pure azole derivatives as inhibitors of Mycobacterium tuberculosis 1.637
Effetti sulla attività di AmB nei confronti di biofilm di C. albicans in seguito ad esposizione a EM01D2 e fluconazolo. 1.621
Novel N-aryl- and N-heteryl-phenazine-1-carboxamides as potential agents for the treatment of infections sustained by drug-resistant and MDR Mycobacterium tuberculosis 1.581
Phenazine-1-carboxilyc acid derivatives suppressing the RNA polymerase as potential agents for the treatment of infections sustained by drug-resistant and MDR Mycobacterium tuberculosis 1.569
Novel N-aryl- and N-heteryl phenazine-1-carboxamides as potential agents for the treatment of infections sustained by drug-resistant and multidrug-resistant Mycobacterium tuberculosis 1.553
Effetto di Inibitori delle COX-1 e COX-2 sullo sviluppo del biofilm di Candida albicans: studio della associazione di FANS e derivati azolici per la profilassi delle infezioni fungine contratte in ambiente ospedaliero 1.514
Identification of a novel pyrrole derivative endowed with antimycobacterial activity and protection index comparable to that of the current antitubercular drugs streptomycin and rifampin 1.503
Synergistic interaction in vitro between rifabutin and newly synthesized S-alkylisothiosemicarbazones derivatives against mycobacterium avium 1.497
Derivati ciclici isotiosemicarbazonici come approccio alternativo nella terapia delle infezioni sostenute da Candida spp. 1.492
dentification of a new Chemical Class of Potent Antimycobacterial Compounds 1.477
BM 579: a novel pyrrole derivative with improved antimycobacterial activity 1.446
Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis 1.432
Design, synthesis and microbiological characterization of 1,5-diphenyl and 1,5-diaryl-2-ethylpyrrole derivatives as new potential agents of infections sustained by MDR and XDR Mycobacterium tuberculosis. 1.396
Nuovo sistema di fermentazione in semi-solido per la produzione di enzimi cellulosolitici 1.391
Synergistic interactions in vitro between Rifabutin and newly synthesized s-alkylthiosemicarbazone derivatives against M. avium 1.325
Sul trattamento microbiologico delle acque di vegetazione 1.305
Infezioni nosocomiali da Pseudomonas maltophilia in un reparto di terapia intensiva per neonat 1.301
Effetto di FANS sulla formazione di biofilm di Candida albicans e potenziamento della attività di farmaci antifungini 1.292
Saggi e dosaggi microbiologici della Farmacopea 1.272
Studio di un metodo rapido mediante riduzione di XTT per la determinazione della resistenza in Mycobacterium tuberculosis 1.244
BM212 and its derivatives: lead optimization of a new class of antimycobacterial agents. 1.236
Pyrrole derivatives of BM212 as novel antimycobacterial agents Design, synthesis, biological evaluation and study of their mode of action 1.201
An investigation of the biological effect of structural modifications of isothiosemicarbazones and their cyclic analogues 1.148
Antimycobacterial Activiy of New 1,4-Benzoxazine-2-one derivatives and its 2-(arylamino)-4-oxobut-2-enoate, ring-open analogues 1.147
null 1.144
New pyrrole derivatives of BM 212: a new class of antimycobacterial agents.Design, synthesis, biological evaluation and study of their mode of action. 1.130
Design and synthesis of 1,5-diaryl-2-ethyl pyrrole derivatives and their evaluation as antimycobacterial agents 1.116
Derivatives of BM 212: synthesis and biological evaluation of new derivatives with improved antimycobacterial activity. 1.076
null 1.070
In vitro antiviral activity of liposomal Artemisia arborescens essential oil 1.065
Synthesis and biological evaluation of some differently substituted 9,10-anthracenediones 1.055
L’OLIO ESSENZIALE DI ARTEMISIA ARBORESCENS INATTIVA HSV1 E HSV2 E INIBISCE LA DIFFUSIONE LATERALE DI CELLULE VERO 1.048
New pyrrole derivatives of BM 212: lead compound optimization strategy, Tuberculosis drug development. Targets, technologies and trials. 1.031
Synthesis and antimicrobial activity of novel arylideneisothiosemicarbazones 993
Attività di un derivato isotiosemicarbazonico ciclico nei confronti di biofilm di Candida albicans FLC-S e FLC-R in combinazione con AMB 956
null 935
PHISICAL STABILITY OF ARTEMISIA ARBORESCENS L. ESSENTIAL OIL LOADED SLN AND IN VITRO ANTIVIRAL ACTIVITY 924
Influenza dell'inclusione liposomiale sull'attività in vitro di miconazolo e ketoconazolo 918
Aumento della sensibilità all’AmB di biofilm di Candida albicans fluconazolo-resistente nell’impiego combinato con derivati ciclici isotiosemicarbazonici 854
Effetti dei liposomi sull'attività in vitro di alcuni antifungini 851
null 826
null 818
L’olio essenziale di Artemisia arborescens inattiva HSV-1 e HSV-2 e inibisce la diffusione laterale in cellule Vero 816
Studio dell’attività di analoghi ciclici isotiosemicarbazonici nei confronti di isolati clinici di Aspergillus spp 781
Aspetti Microbiologici della Produzione Farmaceutica 775
null 764
null 736
Strategie alternative per la profilassi delle infezioni sostenute da Candida albicans contratte in ambiente ospedaliero mediante isotiosemicarbazoni ciclici 734
Isothiosemicarbazones as alternative approach to the therapy of infections sustained by Candida albicans 729
In vitro antimycobacterial activity of newly synthesised S-alkylisothiosemicarbazone derivatives and synergistic interactions in combination with rifamycins against Mycobacterium avium 726
Liposomes as carrier for Artemisia arborescens essential oil: preparation, characterisation and antiviral activity 700
6-Fluorophenylbenzohydrazides inhibit Mycobacterium tuberculosis growth through alteration of tryptophan biosynthesis 692
Studio della attività di una nuova classe di isotiosemicarbazoni nei confronti di Aspergillus spp. di isolamento clinico. 681
Attività intramacrofagica di nuovi agenti antitubercolari per il trattamento delle infezioni sostenute da ceppi MDR mediante inibizione selettiva della RNA polimerasi. 669
Degradazione biologica degli aghi di pino (Pinus Silvester) 663
 and  opiate receptors mediate specific behavioral syndromes from the Substantia Nigra. 640
Saggi e dosaggi microbiologici della Farmacopea 634
Aspetti microbiologici della produzione farmaceutica 632
PHYSICAL STABILITY OF ARTEMISIA ARBORESCENS ESSENTIAL OIL LOADED SLN AND IN VITRO ANTIVIRAL ACTIVITY 608
Stafilococchi 607
null 605
Totale 156.734
Salva come PNG Salva come JPEG
Categoria #
all - tutte 255.651
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 255.651
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.506 0 0 0 0 715 541 389 529 756 769 902 905
2022/202312.524 1.314 1.647 1.447 886 818 1.183 645 1.462 742 620 954 806
2023/202416.879 940 523 1.037 1.211 1.661 3.247 2.625 943 684 1.201 1.491 1.316
2024/202534.953 7.713 11.595 4.674 2.829 1.715 1.663 2.824 277 451 317 443 452
2025/20269.830 490 699 1.088 1.127 500 599 1.264 1.104 663 1.142 685 469
2026/20273.230 438 443 1.068 1.122 159 0 0 0 0 0 0 0
Totale 192.293